Loading
Life sciences · Journal article
BMC Urology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background While HER2-targeted antibody-drug conjugates (ADCs) have shown efficacy in advanced bladder cancer with liver metastases (LM), current guidelines focus on HER2-high (IHC 3+/2+) disease. This case reports a sustained remission in HER2-low (IHC 1+) metastatic urothelial carcinoma (UC) with hepatic dissemination using combination therapy. Case presentation A 73-year-old male presented with painless gross hematuria for three days. Imaging and biopsy confirmed high-grade invasive urothelial carcinoma of the bladder with carcinoma in situ and glandular differentiation. He underwent laparoscopic radical cystectomy with lymph node dissection and ileal conduit diversion. Postoperative pathology showed high-grade invasive urothelial carcinoma, negative lymph nodes, PD-L1 high expression (ICP > 1%, TC 90%) and HER2 (1+). Five months later, surveillance imaging revealed multifocal liver metastases. First-line cisplatin chemotherapy was declined, so he received disitamab vedotin (120 mg every 2 weeks) plus toripalimab (240 mg every 3 weeks). After two cycles, partial response (30% reduction) was achieved, and by 8 cycles near-complete resolution of liver lesions was observed (75% reduction, RECIST 1.1). Transient grade 1 neuropathy was managed by extending the ADC interval to 4 weeks. Treatment was paused after 12 cycles. At 1-year follow-up, the patient maintains sustained remission. Conclusion This hypothesis-generating case suggests that concurrent anti-PD-1 and HER2-targeted ADC may induce deep remission in HER2-low mUC with liver metastases. However, the relative contribution of each agent remains unclear, and high PD-L1 expression alone could explain part of the response. Prospective validation is needed.